Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more
Evogene (EVGN) - Total Liabilities
Latest total liabilities as of September 2025: $6.00 Million USD
Based on the latest financial reports, Evogene (EVGN) has total liabilities worth $6.00 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evogene - Total Liabilities Trend (2011–2024)
This chart illustrates how Evogene's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Evogene Competitors by Total Liabilities
The table below lists competitors of Evogene ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mangalam Global Enterprise Limited
NSE:MGEL
|
India | ₹5.10 Billion |
|
Lambodhara Textiles Limited
NSE:LAMBODHARA
|
India | ₹717.22 Million |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
USA | $14.30 Million |
|
Sundance Strategies Inc
OTCQB:SUND
|
USA | $6.58 Million |
|
Alfa Energi Investama Tbk PT
JK:FIRE
|
Indonesia | Rp108.36 Billion |
|
Heng Huat Resources Group Bhd
KLSE:0175
|
Malaysia | RM34.23 Million |
|
Delek Automotive Systems Ltd
TA:DLEA
|
Israel | ILA8.22 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Evogene's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evogene's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evogene (2011–2024)
The table below shows the annual total liabilities of Evogene from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $25.03 Million | +11.64% |
| 2023-12-31 | $22.42 Million | +5.06% |
| 2022-12-31 | $21.34 Million | +65.60% |
| 2021-12-31 | $12.88 Million | -14.30% |
| 2020-12-31 | $15.03 Million | +34.86% |
| 2019-12-31 | $11.15 Million | +32.89% |
| 2018-12-31 | $8.39 Million | +1.99% |
| 2017-12-31 | $8.22 Million | -5.44% |
| 2016-12-31 | $8.70 Million | -1.65% |
| 2015-12-31 | $8.84 Million | -23.13% |
| 2014-12-31 | $11.50 Million | -8.44% |
| 2013-12-31 | $12.56 Million | -24.30% |
| 2012-12-31 | $16.60 Million | -16.19% |
| 2011-12-31 | $19.80 Million | -- |